Capstone Therapeutics Q2 2025 Results: Gross Margin Jumps to 24.4%, First Acquisition Imminent

Reuters
2025/08/15
Capstone <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Gross Margin Jumps to 24.4%, First Acquisition Imminent

Capstone Holding Corp. (NASDAQ: CAPS) has released its second quarter 2025 financial results, reporting a substantial increase in its gross margin, which rose to 24.4% from 21.4% in the same period the previous year. This improvement is attributed to increased sales of owned brands and disciplined cost management. The company is advancing its acquisition of a Carolina-based stone company, expected to close within the next 10 days. This acquisition is anticipated to be immediately accretive to revenue and EBITDA, expanding Capstone's presence in the high-growth Southeast market. Capstone is targeting a $100 million revenue run-rate by the end of 2025 or the first quarter of 2026, with additional acquisitions under review at attractive valuations. The company has secured flexible capital funding through an Equity Line of Credit and a convertible note, ensuring the availability of funds for future acquisitions without relying on high-interest debt. Looking ahead, Capstone expects a rebound in Q3 order volumes as market conditions stabilize, with potential interest rate cuts in late 2025 providing additional demand support. The company continues to focus on product rollouts and expanding into new territories to maintain momentum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1061481) on August 15, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10